
Product Name: Smad4 Rabbit Polyclonal Antibody**Catalog #: APRab17997**

For research use only.

Summary

Description	Rabbit polyclonal Antibody
Host	Rabbit
Application	WB,IHC,ICC/IF,ELISA
Reactivity	Human,Mouse,Rat,Monkey
Conjugation	Unconjugated
Modification	Unmodified
Isotype	IgG
Clonality	Polyclonal
Form	Liquid
Concentration	1mg/ml
Storage	Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
Shipping	Ice bags
Buffer	Liquid in PBS containing 50% glycerol, 0.5% protective protein and 0.02% New type preservative N.
Purification	Affinity purification

Application

Dilution Ratio	WB 1:500-1:2000,IHC 1:100-1:300,ICC/IF 1:200-1:1000,ELISA 1:5000-1:20000
Molecular Weight	60kDa

Antigen Information

Gene Name	SMAD4 SMAD4; DPC4; MADH4; Mothers against decapentaplegic homolog 4; MAD homolog 4;
Alternative Names	Mothers against DPP homolog 4; Deletion target in pancreatic carcinoma 4; SMAD family member 4; SMAD 4; Smad4; hSMAD4
Gene ID	4089.0
SwissProt ID	Q13485
Immunogen	The antiserum was produced against synthesized peptide derived from human Smad4. AA range:21-70


Background

This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to TGF-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, Oct 2009],disease:Defects in SMAD4 are a cause of juvenile polyposis syndrome (JPS) [MIM:174900]; also known as juvenile intestinal polyposis (JIP). JPS is an autosomal dominant gastrointestinal hamartomatous polyposis syndrome in which patients are at risk for developing gastrointestinal cancers. The lesions are typified by a smooth histological appearance, predominant stroma, cystic spaces and lack of a smooth muscle core. Multiple juvenile polyps usually occur in a number of Mendelian disorders. Sometimes, these polyps occur without associated features as in JPS; here, polyps tend to occur in the large bowel and are associated with an increased risk of colon and other gastrointestinal cancers.,disease:Defects in SMAD4 are a cause of juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome (JP/HHT) [MIM:175050]. JP/HHT syndrome phenotype consists of the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT are autosomal dominant disorders with distinct and non-overlapping clinical features. The former, an inherited gastrointestinal malignancy predisposition, is caused by mutations in SMAD4 or BMPR1A, and the latter is a vascular malformation disorder caused by mutations in ENG or ACVRL1. All four genes encode proteins involved in the transforming-growth-factor-signaling pathway. Although there are reports of patients and families with phenotypes of both disorders combined, the genetic aetiology of this association is unknown.,disease:Defects in SMAD4 are a cause of pancreatic carcinoma [MIM:260350],disease:Defects in SMAD4 may be a cause of colorectal cancer (CRC) [MIM:114500],,function:Common mediator of signal transduction by TGF-beta (transforming growth factor) superfamily; SMAD4 is the common SMAD (co-SMAD). Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. May act as a tumor suppressor.,PTM:Monoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase TRIM33. Monoubiquitination hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade.,similarity:Belongs to the dwarfin/SMAD family.,similarity:Contains 1 MH1 (MAD homology 1) domain.,similarity:Contains 1 MH2 (MAD homology 2) domain.,subcellular location:Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with R-SMAD.,subunit:May form trimers with receptor-regulated SMAD (R-SMAD). Found in a ternary complex composed of SMAD4, STK11 and STK11IP. Interacts with ATF2, COPS5, DACH1, MSG1, SKI, STK11, STK11IP and TRIM33. Associates with ZNF423 or ZNF521 in response to BMP2 leading to activate transcription of BMP target genes. Interacts with USP9X.,


Research Area

Cell_Cycle_G1S;Cell_Cycle_G2M_DNA;WNT;WNT-T CELLTGF-beta;Adherens_Junction;Pathways in cancer;Colorectal cancer;Pancreatic cancer;Chronic myeloid leukemia;


Image Data




Western blot analysis of lysates from HeLa, COS7, HepG2, and HUVEC cells, using Smad4 Antibody. The lane on the right is blocked with the synthesized peptide.




Western blot analysis of the lysates from HT-29 cells using Smad4 antibody.




Immunofluorescence analysis of rat-lung tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-lung tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of mouse-lung tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of mouse-lung tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of mouse-kidney tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B



Immunofluorescence analysis of mouse-kidney tissue. 1, Smad4 Polyclonal Antibody (red) was diluted at 1:200 (4°C, overnight). 2, Cy3 labeled Secondary antibody was diluted at 1:300 (room temperature, 50min). 3, Picture B: DAPI (blue) 10min. Picture A: Target. Picture B: DAPI. Picture C: merge of A+B



Immunohistochemical analysis of paraffin-embedded Human-Tonsil tissue. 1, Smad4 Polyclonal Antibody was diluted at 1:200 (4°C, overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval (>98°C, 20min). 3, Secondary antibody was diluted at 1:200 (room temperature, 30min). Negative control was used by secondary antibody only.